Phase 1 study evaluating the safety and pharmacokinetics of pralatrexate in relapsed/refractory advanced solid tumors and lymphoma patients with mild, moderate, and severe renal impairment.
PURPOSE
Pralatrexate is a folate analogue indicated for the treatment of relapsed or refractory peripheral T-cell lymphoma. It has not been formally tested in patients with renal impairment. This study evaluated the pharmacokinetic (PK) profile of pralatrexate in patients with renal impairment and with relapsed/refractory advanced solid tumors and lymphoma.


METHODS
This was an open-label, nonrandomized, phase 1 study. Eligible patients received pralatrexate administered as an IV push over 3-5 min once weekly for 6 weeks in 7-week cycles until progressive disease or intolerable toxicity. Four cohorts of 6 patients were planned for a total of 24 patients. Patients with normal renal function (Cohort A), mild (Cohort B), and moderate renal impairment (Cohort C) received 30 mg/m2 pralatrexate once weekly for 6 weeks in 7-week cycles, and patients with severe renal impairment (Cohort D) were to be administered 20 mg/m2 once weekly for 6 weeks. Plasma and urine samples were collected at pre-specified time points to determine the PK profile of pralatrexate in each treatment cohort. Patients were followed for safety and tolerability.


RESULTS
A total of 29 patients were enrolled and 27 patients (14 male) received at least 1 dose of pralatrexate. Because of a qualifying toxicity in Cohort C, the starting dose for Cohort D was reduced to 15 mg/m2. Chronic renal impairment led to a decrease in renal clearance of the pralatrexate diastereomers, PDX-10a and PDX-10b, but systemic exposure to these diastereomers was not dramatically affected by renal impairment. Pralatrexate exposure in Cohort D (15 mg/m2) was similar to the exposure in other cohorts (30 mg/m2). No apparent difference in toxicity between the four treatment cohorts was observed, except for an increase in cytopenias in patients with severe renal impairment.


CONCLUSION
Pralatrexate exposure, at a dose of 30 mg/m2, in patients with mild or moderate renal impairment was similar to the exposure in patients with normal renal function. For patients with severe renal impairment only, a pralatrexate dose of 15 mg/m2 is recommended.
['Kelly|Kevin R|KR|', 'Gabrail|Nashat|N|', 'Weitman|Steven|S|', 'Sarantopoulos|John|J|', 'Olszanski|Anthony J|AJ|', 'Edenfield|William|W|', 'Venitz|Jurgen|J|', 'Reddy|Guru|G|', 'Yang|Allen|A|', 'Hasal|Steven J|SJ|', 'Lockhart|A Craig|AC|']
D000328:Adult D000368:Aged D000630:Aminopterin D019008:Drug Resistance, Neoplasm D023381:Endpoint Determination D005260:Female D005493:Folic Acid Antagonists D006801:Humans D007676:Kidney Failure, Chronic D007677:Kidney Function Tests D008223:Lymphoma D008297:Male D008875:Middle Aged D009364:Neoplasm Recurrence, Local D009369:Neoplasms D051437:Renal Insufficiency D013237:Stereoisomerism
Pharmacokinetics Pralatrexate Lymphoma Renal